دورية أكاديمية
Prevalence, incidence and determinants of QuantiFERON TM positivity in South African schoolchildren.
| العنوان: | Prevalence, incidence and determinants of QuantiFERON TM positivity in South African schoolchildren. |
|---|---|
| المؤلفون: | Stewart J; Desmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa., Walker N; Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Jennings K; Health Department, Cape Town Municipality, Cape Town., Delport C; Desmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa., Nuttall J; Paediatric Infectious Diseases Unit, Red Cross War Memorial Children's Hospital, Cape Town.; Department of Paediatrics and Child Health, University of Cape Town, Rondebosch, Cape Town, South Africa., Coussens AK; Infectious Diseases and Immune Defence Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.; Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town., Dyers R; Western Cape Government: Health and Wellness, Cape Town.; Division of Health Systems and Public Health, Department of Global Health, Stellenbosch University, Stellenbosch, South Africa., Jolliffe DA; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London., Tang JCY; Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich.; Departments of Endocrinology and Clinical Biochemistry, Norfolk and Norwich University Hospitals Trust, Norwich., Fraser WD; Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich.; Departments of Endocrinology and Clinical Biochemistry, Norfolk and Norwich University Hospitals Trust, Norwich., Wilkinson RJ; Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town.; The Francis Crick Institute, London.; Department of Infectious Diseases, Imperial College London, London, UK., Bekker LG; Desmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Martineau AR; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London., Middelkoop K; Desmond Tutu HIV Centre, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. |
| المصدر: | IJTLD open [IJTLD Open] 2024 May 01; Vol. 1 (5), pp. 206-214. Date of Electronic Publication: 2024 May 01 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: International Union Against Tuberculosis and Lung Disease Country of Publication: France NLM ID: 9918803487706676 Publication Model: eCollection Cited Medium: Internet ISSN: 3005-7590 (Electronic) Linking ISSN: 30057590 NLM ISO Abbreviation: IJTLD Open Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [Paris, France] : International Union Against Tuberculosis and Lung Disease |
| مستخلص: | Background: TB control requires the understanding and disruption of TB transmission. We describe prevalence, incidence and risk factors associated with childhood TB infection in Cape Town, South Africa. Methods: We report cross-sectional baseline and prospective incidence data from a large trial among primary school children living in high TB burden communities. Prevalent infection was defined as QuantiFERON™-TB Gold Plus (QFT-Plus) positivity as assessed at baseline. Subsequent conversion to QFT-Plus positivity was measured 3 years later among those QFT-Plus-negative at baseline. Multivariable logistic regression models examined factors associated with TB infection. Results: QuantiFERON-positivity at baseline (prevalence: 22.6%, 95% CI 20.9-24.4), was independently associated with increasing age (aOR 1.24 per additional year, 95% CI 1.15-1.34) and household exposure to TB during the participant's lifetime (aOR 1.87, 95% CI 1.46-2.40). QFT-Plus conversion at year 3 (12.2%, 95% CI 10.5-14.0; annual infection rate: 3.95%) was associated with household exposure to an index TB case (aOR 2.74, 95% CI 1.05-7.18). Conclusion: Rates of QFT-diagnosed TB infection remain high in this population. The strong association with household TB exposure reinforces the importance of contact tracing, preventative treatment and early treatment of infectious disease to reduce community transmission. Competing Interests: Conflicts of interest: ARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd (Vejle, Denmark), DSM Nutritional Products Ltd (Heerlen, the Netherlands, Thornton & Ross Ltd (Colne Valley, UK) and Hyphens Pharma Ltd (Singapore City, Singapore). ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd (Walsall, UK) and Cytoplan Ltd (Hanley Swan, UK); support for attending meetings from Pharma Nord Ltd and Abiogen Pharma Ltd (Pisa, Italy); receipt of consultancy fees from DSM Nutritional Products Ltd and Qiagen Ltd (Hilden, Germany); receipt of a speaker fee from the Linus Pauling Institute (Corvallis, OR, USA); participation on Data and Safety Monitoring Boards for the VITALITY Trial (Vitamin D for Adolescents with HIV to reduce musculoskeletal morbidity and immunopathology, Pan African Clinical Trials Registry; ref PACTR20200989766029) and the Trial of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India (ClinicalTrials.gov ref NCT04641195); and unpaid work as a Programme Committee member for the Vitamin D Workshop. All other authors declare that they have no competing interests. (© 2024 The Authors.) |
| References: | Int J Tuberc Lung Dis. 2010 Apr;14(4):406-12. (PMID: 20202297) BMC Infect Dis. 2011 Jun 01;11:156. (PMID: 21631918) N Engl J Med. 2020 Jul 23;383(4):359-368. (PMID: 32706534) Am J Respir Crit Care Med. 2021 Nov 15;204(10):1211-1221. (PMID: 34343025) Pediatrics. 2007 Apr;119(4):734-9. (PMID: 17403844) Int J Tuberc Lung Dis. 2015 May;19(5):596-602. (PMID: 25868030) Front Public Health. 2023 Jan 10;10:997025. (PMID: 36703824) Clin Infect Dis. 2008 Feb 1;46(3):443-6. (PMID: 18173355) Am J Respir Crit Care Med. 2003 Aug 15;168(4):448-55. (PMID: 12773322) S Afr Med J. 2009 Oct;99(10):738-43. (PMID: 20128273) J Nutr Biochem. 2017 Aug;46:21-29. (PMID: 28437713) Clin Infect Dis. 2019 Aug 16;69(5):813-819. (PMID: 30481273) Int J Tuberc Lung Dis. 2011 Nov;15(11):1490-6, i. (PMID: 22008762) Trop Med Int Health. 2015 Jun;20(6):737-43. (PMID: 25704441) Int J Tuberc Lung Dis. 2004 Jun;8(6):718-23. (PMID: 15182141) Int J Tuberc Lung Dis. 2011 Mar;15(3):331-6. (PMID: 21333099) BMC Infect Dis. 2016 Nov 8;16(1):661. (PMID: 27825307) J Infect Chemother. 2021 Dec;27(12):1694-1699. (PMID: 34412980) Annu Rev Public Health. 2013;34:271-86. (PMID: 23244049) PLoS One. 2012;7(6):e39246. (PMID: 22768066) Int J Infect Dis. 2023 Sep;134:63-70. (PMID: 37211272) PLoS Med. 2015 Jun 02;12(6):e1001835; discussion e1001835. (PMID: 26035557) Nutrients. 2022 Mar 16;14(6):. (PMID: 35334921) |
| فهرسة مساهمة: | Keywords: IGRA; QFT-Plus; latent TB; paediatric Local Abstract: [Publisher, French] La lutte contre la TB nécessite la compréhension et la perturbation de la transmission de la TB. Nous décrivons la prévalence, l'incidence et les facteurs de risque associés à l'infection tuberculeuse infantile au Cap, en Afrique du Sud. [Publisher, French] Nous rapportons des données transversales de référence et d'incidence prospective provenant d'un vaste essai mené auprès d'enfants d'écoles primaires vivant dans des communautés à forte charge de morbidité tuberculeuse. La prévalence de l'infection a été définie comme la positivité au QuantiFERON™-TB Gold Plus (QFT-Plus) telle qu'évaluée au départ. La conversion subséquente en QFT-Plus positif a été mesurée 3 ans plus tard chez les QFT-Plus négatifs au départ. Des modèles de régression logistique multivariée ont examiné les facteurs associés à l'infection tuberculeuse. [Publisher, French] La positivité QuantiFERON-au départ (prévalence : 22,6%, IC à 95% 20,9–24,4), était indépendamment associée à l'augmentation de l'âge (aOR 1,24 par année supplémentaire, IC à 95% 1,15–1,34) et à l'exposition du ménage à la TB au cours de la vie du participant (aOR 1,87 ; IC à 95% 1,46–2,40). La conversion QFT-Plus à l'année 3 (12,2%, IC à 95% 10,5–14,0 ; taux d'infection annuel : 3,95%) était associée à l'exposition du ménage à un cas de tuberculose index (aOR 2,74 ; IC à 95% 1,05–7,18). [Publisher, French] Les taux d'infection tuberculeuse diagnostiquée par QFT restent élevés dans cette population. La forte association avec l'exposition à la TB dans les ménages renforce l'importance de la recherche des contacts, du traitement préventif et du traitement précoce des maladies infectieuses pour réduire la transmission communautaire. |
| تواريخ الأحداث: | Date Created: 20240718 Latest Revision: 20240719 |
| رمز التحديث: | 20240719 |
| مُعرف محوري في PubMed: | PMC11249604 |
| DOI: | 10.5588/ijtldopen.24.0084 |
| PMID: | 39022781 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 3005-7590 |
|---|---|
| DOI: | 10.5588/ijtldopen.24.0084 |